Skip to main content
Premium Trial:

Request an Annual Quote

Norak Changes Name to Xsira, Plans Sale of Fluorescent Assay Technology

NEW YORK, Jan. 3 (GenomeWeb News) - Norak Biosciences said this week that it has changed its name to Xsira Pharmaceuticals to reflect its transition from a platform technology company to a product development company.

 

As part of the change, Norak also plans to sell all aspects of its business related to Transfluor, its flagship fluorescent assay technology for screening G-protein coupled receptors.

 

Terry Willard, executive vice president of Xsira, told GenomeWeb News' sister publication Inside Bioassays that the company doesn't yet have a buyer for Transfluor, but that several companies are interested.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.